Supplementary Material, Supplementary Tables 2 through 4, 6 and 7, and Supplementary Figures 1 through 6, 8 through 12, and 14 from Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer

The Supplementary Material File contains specific methodological information as well as additional results related (and cited) in the main manuscript. In particular, it contains six sections providing information on: S1) Experimental validation of drug combinations in human cancer cell lines, S2) Impact of the Residual Standard Error, S3) In vivo xenograf model, S4) Functional relationships among KEGG pathways, S5) Efficacy of clinically relevant drug combinations with respect to the PCI and S6) Enrichment of synergistic combinations in comparison with high-throughput experimental screens.